Loading...
  • immunization
  • Immunization against defined tumor antigens using a xenogeneic DNA vaccine is currently being tested in early phase clinical trials for the treatment of melanoma and prostate cancers, with proposed trials for breast cancer and Non-Hodgkin's Lymphoma. (biomedcentral.com)
  • However, in poorly immunogenic tumor models, which may more closely resemble human disease, prior immunization with tumor vaccines, including DC-based vaccines, was required for CTLA4 blockade to exert robust antitumor effects ( 1 ). (aacrjournals.org)
  • immunogenic
  • In animal models, administration of CTLA4-blocking antibodies alone induced rejection of established tumors, provided that these were immunogenic tumor models ( 1 , 2 ). (aacrjournals.org)
  • 13. The pharmaceutical composition of claim 1 , wherein said composition comprises one or more peptides which are derived from a naturally occurring immunogenic protein or tumor antigen, or a cellular breakdown product thereof. (google.com)
  • immune response
  • Viruses are carefully selected based on their ability to demonstrate selective tumor cell replication, and viral genomic modifications are used to enhance such replication and create a heightened immune response. (springer.com)
  • Defining the structural basis by which CD4+ T cell help is invoked in an anti-tumor immune response will likely aid the design of more effective cancer immunotherapies. (ebi.ac.uk)
  • Taken together, these results suggest that an immune response against MDP-derived Ags may be an important aspect of the patient's ability to control tumor outgrowth. (pubmedcentralcanada.ca)
  • patients
  • We identified circulating CD8+ T-cell populations specific for the tumor-associated antigens (TAAs) MART-1 (27-35) or tyrosinase (368-376) in six of eleven patients with metastatic melanoma using peptide/HLA-A*0201 tetramers. (nih.gov)
  • HLA-A*0201-positive patients with surgically treated melanoma received either a "prime-boost" DNA/MVA or a homologous MVA-only regimen. (ox.ac.uk)
  • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. (nih.gov)
  • Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma. (nih.gov)
  • Breast cancer survival is multifactorial, however, and even patients with small tumors and no evidence of ALN metastasis may ultimately succumb to distant metastasis within 5 years ( 2 ). (aacrjournals.org)
  • Melanomas have no histopathologic, molecular, or immunochemical markers to differentiate subsets of patients. (alpfmedical.info)
  • The identification of melanoma-associated Ags (MAA) 2 and their T cell epitopes has stimulated interest in the development of active specific vaccination of patients with advanced cancer ( 1 , 2 ). (jimmunol.org)
  • The clinical potential of these antigens is hampered by their limited expression in ALL patients or by their restricted presentation by nonprevalent HLA alleles. (aacrjournals.org)
  • The combination was tested in a phase I clinical trial in patients with advanced melanoma. (aacrjournals.org)
  • There was no difference in immune monitoring results between patients with an objective tumor response and those without a response. (aacrjournals.org)
  • We describe the safety, immune effects, and clinical antitumor activity of this combination in patients with metastatic melanoma. (aacrjournals.org)
  • On the other hand non-coding RNAs such as miRNAs and snoRNAs are likely being used as diagnostic or prognostic biomarkers for melanoma patients. (springer.com)
  • Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. (springer.com)
  • Promising results have been obtained in many animal models using these approaches, but they have rarely led to objective and durable anti-tumor effects in cancer patients ( 11 - 14 ). (pnas.org)
  • Most studies in animals use transplantable tumors, which differ in many ways from spontaneously developed (autochthonous) tumors in patients ( 13 - 15 ). (pnas.org)
  • Recently, combination therapy trials with OVs and immune checkpoint inhibitors have shown to have some very promising results in patients with advanced, often metastatic, melanoma. (springer.com)
  • This chapter includes an overview of the history of and making of OVs as well as a detailed summary of current clinical trials in melanoma patients. (springer.com)
  • CTLs specific for MDP-derived Ags have been found in the metastatic LNs of melanoma patients 19 20 , but the presence of these CTLs sometimes correlates with the loss of MDP expression 21 . (pubmedcentralcanada.ca)
  • ligand
  • Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a therapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof. (patents.com)
  • Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 is a Prognostic Factor for Malignant Melanoma Cancer, Apr. (patents.com)
  • molecular
  • By HPLC filtration, the D6.1-defined TAA from detergent-solubilized melanoma cell membranes was determined to have an apparent molecular weight of 150,000 to 280,000 daltons. (duke.edu)
  • These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system. (rupress.org)
  • human leukocy
  • We utilized three separate methodologies for the detection of CTLs in a cohort of HIV-infected individuals who were also human leukocyte antigen A2 (HLA-A2) positive. (asm.org)
  • Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. (ebi.ac.uk)
  • treatment of melanoma
  • With new experimental data on oncolytic virotherapy published in ever-increasing numbers, the future of OVs for the treatment of melanoma seems to hold promise as a major component of treatment for melanoma. (springer.com)
  • Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. (springer.com)
  • proteins
  • Characterization of these "shared" melanoma Ags has established that they are peptides restricted by class I MHC molecules and are derived from a variety of source proteins. (pubmedcentralcanada.ca)
  • immunotherapies
  • We will present in detail the existing immunotherapeutic options that exploit the neoantigen burden of tumors encompassing both preclinical efforts that provided convincing technological proof-of-concept and the current clinical studies confirming the potential of neoantigen-directed immunotherapies. (frontiersin.org)
  • peptides
  • Synthesized peptides corresponding to predicted HLA-A2 binding epitopes showed no differences between inflamed and noninflamed tumors. (pnas.org)
  • 7. The pharmaceutical composition of claim 1 , wherein said peptides are derived from a tumor antigen. (google.com)